Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), an Israel headquartered clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced on Tuesday that the United States Patent and Trademark Office has granted a patent to the company.

The patent is titled 'Methods and Compositions for Treating Diabetes.'

The patent has been granted for the methods and compositions for the treatment of diabetes mellitus via oral pharmaceutical compositions that include insulin in combination with Glucagon-like Peptide 1 (GLP-1).